Dr. Brahmer on the Future of Antibodies for Lung Cancer

Video

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses the future of antibodies, including nivolumab, for the treatment of lung cancer.

Julie R. Brahmer, MD, Associate Professor, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses the future of antibodies, including nivolumab, for the treatment of lung cancer at the 11th Annual International Congress on Targeted Therapies in Cancer.

As more and more monoclonal antibodies are being tested in the clinic, it is enocouraging to see consistent responses across tumor types, Brahmer says. Based on these consistent responses, the oncology community hopes to get these antibodies approved for the treatment of patients with lung cancer.

In addition to continued consistent results, there is hope for a better safety profile with these agents. When responses are seen, Brahmer says, they are often long lasting. Unlike chemotherapy, which typically elicits a response of a few months, the duration of responses seen with nivolumab is unheard of.

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD